Chief Executive Officer
Ben Zimmer serves as Alyvant’s CEO and the President of Roivant Health, where he leads the launch of new companies to improve the drug development and healthcare delivery processes. Ben previously led teams to accelerate clinical trial enrollment at Roivant’s biotechnology companies. Prior to Roivant, he worked as a management consultant at McKinsey & Company and on several start-ups outside the biopharmaceutical sector. He received his A.B. from Harvard and his J.D. from Yale.
Gillian has worked in the pharmaceutical industry for over 30 years in senior US, European and Global leadership positions at multiple pharmaceutical companies including Merck, Otsuka, and UCB. She has expertise across a range of disciplines including Market Access, Sales, Marketing, Business Development and Strategic Planning.
Chief Finance Officer
Nik has over 12 years of experience investing in biotech and pharma companies. For nearly a decade, Nik was a buy-side analyst covering the therapeutics sector at multi-billion dollar hedge funds including Citadel and Soros. Prior to joining Alyvant, Nik was Managing Director at Tourbillon Capital where he managed a $1 B healthcare portfolio dedicated to biotech and pharma investments.
Chief Business Officer
Bob Elliott has 20 years of experience driving success in high performing organizations across disciplines. For the majority of his career, Bob led much of the development of new systematic alpha investment strategies at Bridgewater Associates, the world’s largest hedge fund. While at Bridgewater, Bob proved his interdisciplinary abilities by stretching into building strategic partnerships with institutional investors and policymakers, and managing a range of business disciplines including security and technology.
Senior Vice President of Strategy & Analytics
Maria has worked in the pharmaceutical industry more than 20 years in various commercial appointments. Before Alyvant, she was VP of Commercial Strategy and Analytics in UCB, VP Strategy and Business Analytics at Otsuka Pharmaceuticals, and Executive Director at Merck & Co. in leadership roles in Brand Management and M&A Integration Teams.
Chief Technology Officer
Mitchell has over 35 years of experience in software, both in development and management. He has created platforms for major investment banks and corporations during his tenures at Goldman, Sachs, Bank of America and Amazon. As a founding partner of TraderTools, Mitchell supplied trading systems and real-time data management tools to large companies, including Credit Suisse, Credit Lyonnais, Dresdner, Societe Generale and WestLB.